Gilead Sciences (NASDAQ: GILD) may have a management problem — at least if the market’s sentiment toward this top biotech is a reliable indicator. After all, ever since John Milligan replaced John Martin as Chief Executive Officer last March, Gilead’s shares have dramatically under-performed the broader biotech industry, evidenced by its performance against the iShares Nasdaq Biotechnology ETF: